Vitamin K uptake in chronic kidney disease

Not Applicable

• Conditions: Healthy volunteers; N18; Chronic kidney disease

• Registration Number: DRKS00025281
• Lead Sponsor: niversitätsklinikum der RWTH Aachen

Brief Summary

profound disturbances in lipoprotein mediated vitamin K transport and metabolism in uremia suggest that menaquinone 7 supplementation to patients on dialysis therapy has reduced efficacy.

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-03-28
• Study Start: 2021-05-26
• Results First Posted: 2022-02-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

stable, chronic hemodialysis patients
•Age of = 18 years
•Written informed consent prior to study participation
•The subject is willing and able to follow the procedures
outlined in the protocol
Control group:
•Normal renal function
•Age- and sex-matched written informed consent prior to
study participation
•The subject is willing and able to follow the procedures
outlined in the protocol

Exclusion Criteria

•Age less than 18 years
•Severe medical events within the last three months
•Planned surgery for the duration of the sampling
•Acute/chronic gastrointestinal infections
•Recent or ongoing antibiotic therapy
•Conditions that impair vitamin K uptake or metabolism
(chronic inflammatory bowel disease, intake of vitamin K
antagonists)
•Smokers
•Severe dyslipidemia
•Severe anemia, defined as hemoglobin level less than 9.0
g/dl

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determination of vitamin K content in liporoteins until 6 hrs after ingestion<br>